White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example
posted on 2022-01-06, 09:08authored byAdis journals on behalf of, Christian Jackisch, Federico Manevy, Suzanne Frank, Nicki Roberts, Jason Shafrin
Article full text
The above infographic represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).